Persbericht Biocartis Group NV: Openbaarmaking van uitstaande stemrechtverlenende effecten
December 22, 2022 11:40 ET
|
Biocartis NV
PERSBERICHT: GEREGLEMENTEERDE INFORMATIE22 december 2022, 17:40 CET Openbaarmaking van uitstaande stemrechtverlenende effecten Mechelen, België, 22 december 2022 – Biocartis Group NV...
Press release Biocartis Group NV: Disclosure of Outstanding Voting Securities
December 22, 2022 11:40 ET
|
Biocartis NV
PRESS RELEASE: REGULATED INFORMATION22 December 2022, 17:40 CET Disclosure of Outstanding Voting Securities Mechelen, Belgium, 22 December 2022 – Biocartis Group NV (the "Company" or "Biocartis"),...
Celyad Oncology provides an update on its strategic business model, continuing to focus on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property
December 21, 2022 01:00 ET
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on the discovery and development of...
Sosei Heptares' Partner Pfizer Progresses its Oral GLP-1 Receptor Agonist PF-07081532 into Phase 2 Clinical Trials for Treating Type 2 Diabetes and Obesity
December 20, 2022 19:01 ET
|
Sosei Group Corporation
PF-07081532 is the first clinical candidate from multi-target drug discovery collaboration to advance into Phase 2 trialsDosing of first subject in Phase 2 trial by Pfizer triggers payment of US$10...
Insilico Medicine Nominates Potential First-in-Class Preclinical Candidate with Novel AI-Designed Structure for Novel AI-Discovered Target in Immuno-oncology
December 20, 2022 09:00 ET
|
InSilico Medicine
New York, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Insilico Medicine (“Insilico”), a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, today announced that the company...
Sosei Heptares to present at 41st Annual J.P. Morgan Healthcare Conference
December 20, 2022 01:30 ET
|
Sosei Group Corporation
TOKYO and CAMBRIDGE, United Kingdom, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565) announces its President & CEO Chris Cargill will present at the 41st...
Bionomics Reports Topline Results in PREVAIL Phase 2 Study of BNC210 in Social Anxiety Disorder
December 18, 2022 19:34 ET
|
Bionomics Ltd
BNC210 for Treatment of Social Anxiety Disorder (SAD) Did Not Meet Primary EndpointSubjects with Confirmed SAD who Received BNC210 Exhibited Trends Toward Improvements Across Endpoints Compared to...
Persbericht Biocartis Group NV: Voltooiing van verplichte conversie
December 16, 2022 11:40 ET
|
Biocartis NV
PERSBERICHT: GEREGLEMENTEERDE INFORMATIE16 december 2022, 17:40 CET Voltooiing van Verplichte Conversie Bepalingen met een hoofdletter in deze kennisgeving die niet werden gedefinieerd zullen de...
Press release Biocartis Group NV: Completion of Mandatory Conversion
December 16, 2022 11:40 ET
|
Biocartis NV
PRESS RELEASE: REGULATED INFORMATION16 December 2022, 17:40 CET Completion of Mandatory Conversion Capitalized terms not otherwise defined in this notice shall have the meaning given to them in the...
Ocugen Announces Phase 3 Confirmatory Clinical Trial Agreement for NeoCart®
December 16, 2022 06:30 ET
|
Ocugen
MALVERN, Pa., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...